Tom Powles

Dr. Tom Powles and Dr. Brian Rini discuss 2023 updates for metastatic bladder cancer, including staging, treatment options, and variant histologies. They highlight the efficacy and adverse event profile of single agent pembrolizomab and mabidotin. The podcast also covers new drugs in oncology and treatment options for urethral carcinoma. Additionally, they discuss less common histologic types of bladder cancer and the challenges of variant histologies for personalized treatment approaches.

Dr. Tom Powles and Dr. Brian Rini discuss 2023 updates for localized bladder cancer, including diagnostic workup, staging, and treatment options. They share mixed opinions on a trial and challenges in therapy, express skepticism towards PET scans, and explore various treatment options. Exciting insights from the urologic oncology experts!

Dr. Tom Powles and Dr. Brian Rini, experts in urologic oncology and renal cell carcinoma, delve into groundbreaking updates for metastatic kidney cancer. They discuss the IMDC classification and its role in risk assessment, emphasizing patient selection for treatments. Treatment strategies, including the balance between aggressive therapies and patient well-being, are explored. The duo also addresses challenges in non-clear cell variants and highlights the potential of emerging therapies. Finally, they share valuable advice for early-career oncologists, stressing the importance of mentorship.